TrialProceedings of the National Academy of Sciences of the United States of America2008

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Jianda Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.